Briquilimab (JSP-191) 是一种无毒的人源化单克隆抗体,靶向 CD117 (c-Kit),用于耗尽造血干细胞 (HSC)。Briquilimab 作为重度联合免疫缺陷 (SCID) 的主要方法,可清除宿主骨髓生态位空间,实现足够的供体造血干细胞移植和免疫重建。
生物活性 | Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID)[1]. |
IC50& Target | |
CAS 号 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |